JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265802

Human PPP1R13L (iASPP) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PPP1R13L KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 2 bp deletion in exon 4.

View Alternative Names

Inhibitor of ASPP protein, NFkB interacting protein 1, NKIP1, PPP1R13B-like protein, PPP1R13L, Protein iASPP, RAI, RelA-associated inhibitor, inhibitor of apoptosis stimulating protein of p53, protein phosphatase 1 regulatory (inhibitor) subunit 13 like

2 Images
Sanger Sequencing - Human PPP1R13L (iASPP) knockout HeLa cell line (AB265802)
  • Sanger seq

Unknown

Sanger Sequencing - Human PPP1R13L (iASPP) knockout HeLa cell line (AB265802)

Allele-1 : 2 bp deletion in exon 4.

Sanger Sequencing - Human PPP1R13L (iASPP) knockout HeLa cell line (AB265802)
  • Sanger seq

Unknown

Sanger Sequencing - Human PPP1R13L (iASPP) knockout HeLa cell line (AB265802)

Allele-2 : 1 bp insertion in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 2 bp deletion in exon 4

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265802-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265802 Human PPP1R13L (iASPP) knockout HeLa cell line", "number":"AB265802-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265802-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265802 Human PPP1R13L (iASPP) knockout HeLa cell line", "number":"AB265802-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PPP1R13L
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

IASPP also known as inhibitor of apoptosis-stimulating protein of p53 is a regulatory protein with a mass of approximately 96 kDa. It plays an important role in modulating apoptosis functioning as a negative regulator of p53 a well-known tumor suppressor protein. iASPP binds directly to p53 preventing its ability to transactivate target genes associated with cell cycle arrest and apoptosis. This protein is widely expressed in various tissues suggesting its importance in cellular homeostasis and response to stress.
Biological function summary

IASPP negatively affects p53-mediated apoptosis and cellular senescence. It is part of a complex with PP1 acting as a regulatory subunit that influences several cellular processes by modulating dephosphorylation activities. iASPP's interaction with PP1 further impacts gene expression by affecting the phosphorylation status of various transcription factors. This regulatory mechanism suggests iASPP plays a role in controlling cell growth and death essential processes for maintaining normal cellular function.

Pathways

IASPP modulates the p53 pathway an essential mechanism for regulating cell cycle and apoptosis. Within this pathway it associates with proteins like ASPP1 ASPP2 and other family members which also influence p53 activity. iASPP has a role in the NF-kB pathway where it influences inflammation and immune responses. Through these pathways iASPP coordinates signals that determine cellular fate connecting it to fundamental processes in cell biology.

IASPP alterations associate with cancer development and progression. Its overexpression often correlates with enhanced tumor growth due to impaired p53 activity. Studies link iASPP to diseases like acute myeloid leukemia (AML) and prostate cancer. Through its interaction with p53 and proteins such as ASPP1 and ASPP2 iASPP provides a potential therapeutic target where modulating its activity might restore proper cellular responses to stress counteracting tumor development.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com